» Articles » PMID: 37490913

T Cell Reactivity to Bordetella Pertussis is Highly Diverse Regardless of Childhood Vaccination

Abstract

The incidence of whooping cough due to Bordetella pertussis (BP) infections has increased recently. It is believed that the shift from whole-cell pertussis (wP) vaccines to acellular pertussis (aP) vaccines may be contributing to this rise. While T cells are key in controlling and preventing disease, nearly all knowledge relates to antigens in aP vaccines. A whole-genome mapping of human BP-specific CD4+ T cell responses was performed in healthy vaccinated adults and revealed unexpected broad reactivity to hundreds of antigens. The overall pattern and magnitude of T cell responses to aP and non-aP vaccine antigens are similar regardless of childhood vaccination, suggesting that asymptomatic infections drive the pattern of T cell reactivity in adults. Lastly, lack of Th1/Th2 polarization to non-aP vaccine antigens suggests these antigens have the potential to counteract aP vaccination Th2 bias. These findings enhance our insights into human T cell responses to BP and identify potential targets for next-generation pertussis vaccines.

Citing Articles

Prevalence of among children aged 4 years and above presenting with acute respiratory tract infection: a cross-sectional study.

Binti Md Bahar A, Muhamad A, Teh C, Adnan M, Adam S, Hng S Pathog Glob Health. 2024; 118(7-8):582-586.

PMID: 39244781 PMC: 11892038. DOI: 10.1080/20477724.2024.2400412.


Adaptive immune response to bordetella pertussis during vaccination and infection: emerging perspectives and unanswered questions.

Kim A, Sette A, Da Silva Antunes R Expert Rev Vaccines. 2024; 23(1):705-714.

PMID: 39037200 PMC: 11306532. DOI: 10.1080/14760584.2024.2383745.


Understanding the impact of adult pertussis and current approaches to vaccination: A narrative review and expert panel recommendations.

Kardos P, Correia de Sousa J, Heininger U, Konstantopoulos A, MacIntyre C, Middleton D Hum Vaccin Immunother. 2024; 20(1):2324547.

PMID: 38564339 PMC: 10989709. DOI: 10.1080/21645515.2024.2324547.


Bordetella spp. block eosinophil recruitment to suppress the generation of early mucosal protection.

First N, Parrish K, Martinez-Perez A, Gonzalez-Fernandez A, Bharrhan S, Woolard M Cell Rep. 2023; 42(11):113294.

PMID: 37883230 PMC: 11682855. DOI: 10.1016/j.celrep.2023.113294.

References
1.
Sette A, Moutaftsi M, Moyron-Quiroz J, McCausland M, Davies D, Johnston R . Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity. 2008; 28(6):847-58. PMC: 2504733. DOI: 10.1016/j.immuni.2008.04.018. View

2.
Creech C, Jimenez-Truque N, Kown N, Sokolow K, Brady E, Yoder S . Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults. Vaccine. 2022; 40(47):6740-6746. DOI: 10.1016/j.vaccine.2022.09.075. View

3.
Wilk M, Borkner L, Misiak A, Curham L, Allen A, Mills K . Immunization with whole cell but not acellular pertussis vaccines primes CD4 T cells that sustain protective immunity against nasal colonization with Bordetella pertussis. Emerg Microbes Infect. 2019; 8(1):169-185. PMC: 6455184. DOI: 10.1080/22221751.2018.1564630. View

4.
Yu E, Narowski T, Wang E, Garrigan E, Mateus J, Frazier A . Immunological memory to common cold coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic. Cell Host Microbe. 2022; 30(9):1269-1278.e4. PMC: 9296686. DOI: 10.1016/j.chom.2022.07.012. View

5.
Blanchard-Rohner G . Novel approaches to reactivate pertussis immunity. Expert Rev Vaccines. 2022; 21(12):1787-1797. DOI: 10.1080/14760584.2022.2149499. View